SlideShare a Scribd company logo
Interpretation of Clinical Lab
Data [CARDIAC] for Newbies
Common symptoms of heart disease
 Chest pain (dull, aching tightness rather than tight
stabbing sensation);
 Dyspnoea; Palpitations; Dizziness; Syncope; Oedema;
Diagnostic Testing
 Chest X-Ray (CXR): Provides info. about heart size,
pulmonary circulation, and aortic abnormalities.
 Echocardiogram: provides more reliable info. about
chamber size, hypertrophy, valvular and congenital
abnormalities.
 Electrocardiogram (ECG): Indicates the cardiac rhythm;
reveals conduction abnormalities; provides evidence of
ventricular hypertrophy, MI, Ischemia.
ECG
 Angina Pectoris: ST depression; Flat (inverted) T-wave
 STEMI:
• 1st ECG change during STEMI is ‘hyperacute T waves’ which
appear peaked and are related to localized hyperkalemia. These
changes are rarely seen as they are transient and frequently
occur prior to hospital arrival.
• ST segment elevation (pertaining to the affected myocardium).
• 1 mm of ST elevation in 2 contiguous leads is required
to diagnose STEMI,
• ST elevations are indicative of the ischemic area.
Q
R
S
 NSTEMI and Unstable angina:
• ST-segment depression≥ 0.5 mm; negative (inverted or flat) T-
waves≥ 1.0 mm
• ST depressions do NOT localize to the ischemic area
• ECG cannot be used to determine the location of ischemia in
patients w/ NSTEMI and unstable angina.
Q
R
S
Ischemic ST depression is characterized by horizontal or
downward sloping (if not, then ischemia is unlikely to be the
cause).
If QRS….
• > 100/min. → Tachycardia;
• < 60/min. → Bradycardia;
Q
R
S
Exercise Stress Testing (EST or ET or ETT)
 Is a test of myocardial perfusion; also determines
the adequacy of CV functions;
 Evaluates clinical and CV responses to exercise;
 Used as a diagnostic and prognostic assessment in
patients with known or suspected IHD.
 Non-invasive test (conducted on a tread mill or bicycle
ergometer);
 Treadmill walking is preferred over the ergometer as it
involves more muscle mass.
EST (contd’.)
 Principle: Controlled method to assess the balance between
myocardial O2 demand and coronary blood flow under ‘stress’
(exercise is the stressor).
 A (+) ET is defined as ‘1mm horizontal or downsloping
depression, or elevation of the ST segment for 60-80
milliseconds after the QRS complex’.
Nuclear Imaging
 Used to detect MI or to measure myocardial function,
perfusion or viability depending on the
radiopharmaceutical used and the technique of
imaging.
 Thallium-201 (TL-201):
• Rapidly taken up by the myocardium;
• An image taken immediately after injection reflects the
distribution of blood flow to the myocardium.
• Areas of ischemia or infarction receive less TL-201 and
appear dark.
• Around 2 - 6 hrs. post-injection, TL-201 redistributes so
that all cardiac myocytes contain a comparable
concentration. Images at this time show dark areas
(infarction) but normal density in ischemic areas.
 The hypoperfused areas of the viable myocardium
which had little or no TL-201 initially are called ‘Partial
Defects’.
 Redistribution occurs because there is a delayed
washout of TL-201 from the poorly perfused
myocardium resulting in less contrast between the
density of TL-201 in different areas of the heart. This
gives the appearance of redistribution into the
previously ischemic areas.
 To enhance the evaluation of the partial defects, a
second injection of TL-201 can be used.
 Areas of nil distribution are called ‘Cold Spots’ or ‘Fixed
defects’ (representing infarcted myocardium).
Scope of TL-201 imaging:
 Useful for patients w/
• atypical chest pain to determine if IHD is the cause of
symptoms.
• ambiguous or false-positive ETT to determine the ETT
abnormalities.
 The finding of redistribution is a marker of jeopardized
but viable myocardium that has important prognostic
value.
 Tc-99: To detect myocardial viability.
 Antimyosin Abs: Highly specific, so, should be more
better markers of myocyte necrosis. But, uptake into
myocardial tissues is very low; localization is more
dependent on blood flow rather than on myosin conc.
 Phyenylpentadecanoic acid: assesses both myocardial
perfusion and metabolism by virtue of it’s affinity for
fatty acid metabolism.
Pharmacological Stress Testing
 Alternative to ETT
 For patients who are unwilling or unable to undergo
ETT;
 Used to assess coronary perfusion;
 P’cological agent produces stress by…
• hyperemic (vasodilator) response,
[OR]
• ↑es myocardial O2 demand (heart rate and myocardial
contractility);
 Agents used:
• Dipyridamole and Adenosine (hyperemic stress), and
• Dobutamine (cardiac stress)
Principle of Dipyridamole and Adenosine TL-201 scanning:
 Related to the coronary arteriolar vasodilator props.
 Dipyridamole inhibits adenosine reuptake by cells;
causing an ↑ ed conc. of adenosine.
 Adenosine is a very potent coronary artery vasodilator
(↑es the perfusion).
 Areas distal to the coronary will be hypoperfused; but
these areas will get filled on redistribution indicating
viable but jeopardized myocardium.
 Optimal dose (based on numerous research articles):
• Dipyridamole 0.142 mg/kg per min. over 4 mins.
• Adenosine 0.140 mcg/kg per min. over 6 mins.
 TL-201 (2.5 – 4 mCi) is administered…
• immediately after inf. of dipyridamole,
(or)
• after 3 mins. of Adenosine inf.
 Onset of action:
• Dipyridamole (5-7 mins. post-inf.);
• Adenosine (approx. 30 secs. post-inf.);
Dobutamine:
 Synthetic catecholamine;
 ↑es heart rate and cardiac output ↑es myocardial
O2 demand.
 Ischemia develops in areas where there is ↑ in O2
demand (by stenosis which prevents the blood flow to
those areas).
 This can be detected by the TL-201 scanning….
• Dobutamine dose 10 – 20 mcg/kg per min.
• TL-201 is administered 2-3 mins. before inf. ends.
 β-blockers and CCBs may interfere w/ the heart’s
response to the Dobutamine stress test.
(Recommendation: Discontinue the Tx prior to the
test).
 Contraindicated: Aortic stenosis, uncontrolled HTN,
severe ventricular arrhythymias;
Dobutamine stress testing…
 Post-MI, this test identifies patients at high risk of
subsequent cardiac events.
 For patients w/ suspected or k/c/o IHD,…
• a positive result is an independent predictor of ‘cardiac
events’;
• a negative result indicates protection from cardiac death.
 Showed higher diagnostic accuracy (82%) for IHD;
against 87% for ETT, and 77% for dipyridamole;
 Showed high sensitivity (80%) – review of 14 studies;
942 IHD patients;
 Cardiac catheterization
 CT scan; MRI scan
Cardiac Enzymes
Lactate Dehydrogenase (LDH1 to LDH5)
 Highly distributed throughout the body w/ high concs.
in the heart muscle, skeletal muscle, liver, kidney,
brain, and RBCs.
 LDH1, LDH2 (mainly in the heart);
 LDH3 (lungs);
 LDH4, LDH5 (mainly in the liver and skeletal muscles);
 LDH1 is often measured after a suspected MI. This
isoenzyme shows greater catalytic activity combined w/
α-OH butyrate. This substrate is measured. Post-MI,
peak serum levels are achieved after 2-3 days, then
declines over 7 days or more.
LDH (contd’.)
 LDH1 and LDH2: ↑es after MI, renal infarction,
megaloblastic anaemia;
 LDH2 and LDH3: ↑es after acute leukemia;
 LDH5: ↑es after damage to liver or skeletal muscle;
Creatine Kinase (CK)
 Relatively high concs. in heart muscles, skeletal muscles,
smooth muscles, brain.
 Markedly ↑ed after circulation failure, MI, muscular
dystrophies, exercise, and trauma.
 CK has 2 protein subunits: M and B (which combine to form 3
isoenzymes BB, MM, and MB).
 Cardiac tissues contain more of the CK-MB isoenzyme.
 CK-MM (skeletal muscle); CK-BB (brain tissue);
 ↑ed CK-MB levels indicate myocardial necrosis.
Enzymes Rise (hrs.) Peak (hrs.) Falls
CK-MB 4 – 6 12 48 – 72 hrs.
LDH 12 48 – 72 7 days
AST 12 24 48 hrs.
Aspartate aminotransferase (AST)
 Formerly known as Serum Glutamic-Oxaloacetic
Transaminase (SGOT);
 Found mainly in the cardiac and hepatic tissues;
 To a lesser extent in the skeletal muscle, kidney
tissue and pancreatic tissue.
 ↑ed AST levels are seen 8 hrs. post-damage to the
heart from MI.
Alanine aminotransferase (ALT)
 Formerly known as Serum Glutamic-Pyruvic
Transaminase (SGPT);
 Mainly in the liver;
 To a lesser extent in the heart, skeletal muscles, and
kidneys;
 ALT ↑es less consistently and less markedly than
AST post-MI.
Cardiac Troponins ( ‘I’ and ‘T’)
 Used in the diagnosis of MI;
 Troponin-I (< 1.5 ng/ml); Troponin-T (< 0.1 ng/ml);
 Troponin-I (only in cardiac muscle);
 Troponin-T (in cardiac and skeletal muscles);
 Troponin-T has shown prognostic value in unstable
angina and detecting minor myocardial injury w/
greater sensitivity than CK-MB.
THE END
(FYI Snippets follow….)
 P-wave (2.5 mm): R and L atrial depolarization
 QRS complex (120 ms): R and L ventricular depolarization
 ST segment: phase 2 of ventricular repolarization
 T-wave: rapid phase 3 of ventricular repolarization;
 J-point: the end of QRS and beginning of ST segment is called J-point.
 PR interval: extends from beginning of P wave to beginning of the
QRS. This interval measures the time from the initial depolarization of
the atria to the initial depolarization of the ventricles, and reflects a
physiological delay in AV conduction imposed by the AV node.
Normal range is 120 – 200 ms (3 to 5 1-mm-divisions) and no longer.
 QT interval: is measured from the beginning of the QRS to the end of
the T wave. It represents the time in which the ventricles depolarize
and repolarize and is a measure of ventricular action potential (AP)
duration. Normal intervals are < 460 ms for women and < 450 ms for
men. But QT values are heart-rate dependent and can vary from 270
ms at a heart rate of 150 beats/min to 500 ms at a heart rate of 40
beats/min.
 FYI:
• Anterior STEMI requires 2 mm of ST elevation in V2 and V3 in men >
40 years of age (ACC/AHA definition). A total of 2.5 mm elevation is
required in men < 40 years of age, and only 1.5 mm elevation is
required in women.
• Posterior STEMI frequently has ST depression in V1-V3 instead of
elevation since the vectors are completely reversed. If a posterior
ECG were obtained, ST elevation will be seen in V7-V9, although
sometimes subtle. Since these posterior changes occur from coronary
thrombosis and urgent treatment is needed, it is classified as a
STEMI.
• (courtesy ACC and AHA)
• What is V1-V9????

More Related Content

Similar to Interpretation of Clinical Lab Data [CARDIAC] for newbies.pdf

Acute Coronary Syndrome - Overview
Acute Coronary Syndrome - OverviewAcute Coronary Syndrome - Overview
Acute Coronary Syndrome - Overview
Rahul Varshney
 
MI Myocarditis.pptx internl medicine heart
MI Myocarditis.pptx internl medicine heartMI Myocarditis.pptx internl medicine heart
MI Myocarditis.pptx internl medicine heart
Dinu85
 
ACUTE CORONARY SYNDROME FOR CRITICAL CARE
ACUTE CORONARY SYNDROME FOR CRITICAL CAREACUTE CORONARY SYNDROME FOR CRITICAL CARE
ACUTE CORONARY SYNDROME FOR CRITICAL CARE
AbhinovKandur
 
ACUTE CORONARY SYNDROME
ACUTE CORONARY SYNDROMEACUTE CORONARY SYNDROME
ACUTE CORONARY SYNDROME
KELVIN KANDIRA
 
STEMI-LEO.pptx
STEMI-LEO.pptxSTEMI-LEO.pptx
STEMI-LEO.pptx
MisaleHaile
 
Cardiovascular tests by atika siddiqua
Cardiovascular tests by atika siddiquaCardiovascular tests by atika siddiqua
Cardiovascular tests by atika siddiqua
PARUL UNIVERSITY
 
Cardiovascular tests
Cardiovascular testsCardiovascular tests
Cardiovascular tests
AtikaSiddiqua
 
Cardiovascular testing
Cardiovascular testingCardiovascular testing
Cardiovascular testing
AtikaSiddiqua
 
Coronary Artery Disease
Coronary Artery DiseaseCoronary Artery Disease
Coronary Artery Disease
garimabhardwaj31
 
Myocardial infraction
Myocardial infractionMyocardial infraction
Myocardial infraction
Dr. Savy P. Minal
 
Stemi in the young
Stemi in the youngStemi in the young
Stemi in the young
Akhionbare Ikponmwosa
 
ACS 071509
ACS 071509ACS 071509
ACS 071509
aab2041
 
Analysis of various investigations in myocardial infarction.pptx
Analysis of various investigations in myocardial infarction.pptxAnalysis of various investigations in myocardial infarction.pptx
Analysis of various investigations in myocardial infarction.pptx
Aravind Bhagavath
 
Recent advances in the role of Cardiac bio-markers for clinical practice
Recent advances in the role of Cardiac bio-markers for clinical practiceRecent advances in the role of Cardiac bio-markers for clinical practice
Recent advances in the role of Cardiac bio-markers for clinical practice
subramaniam sethupathy
 
Acute Coronary Syndrome
Acute Coronary SyndromeAcute Coronary Syndrome
Acute Coronary Syndrome
Brian Wells, MD, MS, MPH
 
Cardiac diagnostics and laboratory tests
Cardiac diagnostics and laboratory tests Cardiac diagnostics and laboratory tests
Cardiac diagnostics and laboratory tests
Dr. Rima Das
 
11111801_Myocardial_infarction.ppt
11111801_Myocardial_infarction.ppt11111801_Myocardial_infarction.ppt
11111801_Myocardial_infarction.ppt
ssuser4a6ed4
 
Myocardial infarction
Myocardial infarction Myocardial infarction
Myocardial infarction
vani
 
Anaesthetic Management of a Patient with Ischaemic Heart Disease
Anaesthetic Management of a Patient with Ischaemic Heart DiseaseAnaesthetic Management of a Patient with Ischaemic Heart Disease
Anaesthetic Management of a Patient with Ischaemic Heart DiseaseZareer Tafadar
 

Similar to Interpretation of Clinical Lab Data [CARDIAC] for newbies.pdf (20)

Acute Coronary Syndrome - Overview
Acute Coronary Syndrome - OverviewAcute Coronary Syndrome - Overview
Acute Coronary Syndrome - Overview
 
MI Myocarditis.pptx internl medicine heart
MI Myocarditis.pptx internl medicine heartMI Myocarditis.pptx internl medicine heart
MI Myocarditis.pptx internl medicine heart
 
ACUTE CORONARY SYNDROME FOR CRITICAL CARE
ACUTE CORONARY SYNDROME FOR CRITICAL CAREACUTE CORONARY SYNDROME FOR CRITICAL CARE
ACUTE CORONARY SYNDROME FOR CRITICAL CARE
 
ACUTE CORONARY SYNDROME
ACUTE CORONARY SYNDROMEACUTE CORONARY SYNDROME
ACUTE CORONARY SYNDROME
 
STEMI-LEO.pptx
STEMI-LEO.pptxSTEMI-LEO.pptx
STEMI-LEO.pptx
 
Cardiovascular tests by atika siddiqua
Cardiovascular tests by atika siddiquaCardiovascular tests by atika siddiqua
Cardiovascular tests by atika siddiqua
 
Cardiovascular tests
Cardiovascular testsCardiovascular tests
Cardiovascular tests
 
Cardiovascular testing
Cardiovascular testingCardiovascular testing
Cardiovascular testing
 
Coronary Artery Disease
Coronary Artery DiseaseCoronary Artery Disease
Coronary Artery Disease
 
Myocardial infraction
Myocardial infractionMyocardial infraction
Myocardial infraction
 
Stemi in the young
Stemi in the youngStemi in the young
Stemi in the young
 
ACS 071509
ACS 071509ACS 071509
ACS 071509
 
Analysis of various investigations in myocardial infarction.pptx
Analysis of various investigations in myocardial infarction.pptxAnalysis of various investigations in myocardial infarction.pptx
Analysis of various investigations in myocardial infarction.pptx
 
Recent advances in the role of Cardiac bio-markers for clinical practice
Recent advances in the role of Cardiac bio-markers for clinical practiceRecent advances in the role of Cardiac bio-markers for clinical practice
Recent advances in the role of Cardiac bio-markers for clinical practice
 
Acute Coronary Syndrome
Acute Coronary SyndromeAcute Coronary Syndrome
Acute Coronary Syndrome
 
Cardiac diagnostics and laboratory tests
Cardiac diagnostics and laboratory tests Cardiac diagnostics and laboratory tests
Cardiac diagnostics and laboratory tests
 
CHD
CHDCHD
CHD
 
11111801_Myocardial_infarction.ppt
11111801_Myocardial_infarction.ppt11111801_Myocardial_infarction.ppt
11111801_Myocardial_infarction.ppt
 
Myocardial infarction
Myocardial infarction Myocardial infarction
Myocardial infarction
 
Anaesthetic Management of a Patient with Ischaemic Heart Disease
Anaesthetic Management of a Patient with Ischaemic Heart DiseaseAnaesthetic Management of a Patient with Ischaemic Heart Disease
Anaesthetic Management of a Patient with Ischaemic Heart Disease
 

More from samthamby79

THE 7-STAR PHARMACIST.pdf
THE 7-STAR PHARMACIST.pdfTHE 7-STAR PHARMACIST.pdf
THE 7-STAR PHARMACIST.pdf
samthamby79
 
VARIOUS LAB TESTS INTERPRETATION - AN INTRO..pdf
VARIOUS LAB TESTS INTERPRETATION - AN INTRO..pdfVARIOUS LAB TESTS INTERPRETATION - AN INTRO..pdf
VARIOUS LAB TESTS INTERPRETATION - AN INTRO..pdf
samthamby79
 
INTERPRETATION OF RENAL FUNCTION TESTS.pdf
INTERPRETATION OF RENAL FUNCTION TESTS.pdfINTERPRETATION OF RENAL FUNCTION TESTS.pdf
INTERPRETATION OF RENAL FUNCTION TESTS.pdf
samthamby79
 
INTERPRETATION OF HEPATIC FUNCTION TESTS.pdf
INTERPRETATION OF HEPATIC FUNCTION TESTS.pdfINTERPRETATION OF HEPATIC FUNCTION TESTS.pdf
INTERPRETATION OF HEPATIC FUNCTION TESTS.pdf
samthamby79
 
INTERPRETATION OF PFTs.pdf
INTERPRETATION OF PFTs.pdfINTERPRETATION OF PFTs.pdf
INTERPRETATION OF PFTs.pdf
samthamby79
 
HAEMATOLOGICAL TESTS INTERPRETATION.pdf
HAEMATOLOGICAL TESTS INTERPRETATION.pdfHAEMATOLOGICAL TESTS INTERPRETATION.pdf
HAEMATOLOGICAL TESTS INTERPRETATION.pdf
samthamby79
 
PHARMACOTHERAPY POINTERS FOR ISCHEMIC STROKE [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ISCHEMIC STROKE [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR ISCHEMIC STROKE [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ISCHEMIC STROKE [MALAYSIAN CPGs].pdf
samthamby79
 
PHARMACOTHERAPY POINTERS FOR ANXIETY & AFFECTIVE DISORDERS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ANXIETY & AFFECTIVE DISORDERS [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR ANXIETY & AFFECTIVE DISORDERS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ANXIETY & AFFECTIVE DISORDERS [MALAYSIAN CPGs].pdf
samthamby79
 
PHARMACOTHERAPY POINTERS FOR SCHIZOPHRENIA [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR SCHIZOPHRENIA [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR SCHIZOPHRENIA [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR SCHIZOPHRENIA [MALAYSIAN CPGs].pdf
samthamby79
 
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
samthamby79
 
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdfPHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
samthamby79
 
Interpretation of Clinical Lab Data [PFTs] for Newbies.pdf
Interpretation of Clinical Lab Data [PFTs] for Newbies.pdfInterpretation of Clinical Lab Data [PFTs] for Newbies.pdf
Interpretation of Clinical Lab Data [PFTs] for Newbies.pdf
samthamby79
 
TDM Pointers - Salicylates & Paracetamol Poisoning.pdf
TDM Pointers - Salicylates & Paracetamol Poisoning.pdfTDM Pointers - Salicylates & Paracetamol Poisoning.pdf
TDM Pointers - Salicylates & Paracetamol Poisoning.pdf
samthamby79
 
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdfTDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
samthamby79
 
Dosage adjustment in Hepatic Failure.pdf
Dosage adjustment in Hepatic Failure.pdfDosage adjustment in Hepatic Failure.pdf
Dosage adjustment in Hepatic Failure.pdf
samthamby79
 
Drug Dosing in Renal Failure.pdf
Drug Dosing in Renal Failure.pdfDrug Dosing in Renal Failure.pdf
Drug Dosing in Renal Failure.pdf
samthamby79
 
BIOAVAILABILITY IN A NUTSHELL.pdf
BIOAVAILABILITY IN A NUTSHELL.pdfBIOAVAILABILITY IN A NUTSHELL.pdf
BIOAVAILABILITY IN A NUTSHELL.pdf
samthamby79
 
GENERIC AND SPECIFIC INSTRUMENTS IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
GENERIC AND SPECIFIC INSTRUMENTS IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdfGENERIC AND SPECIFIC INSTRUMENTS IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
GENERIC AND SPECIFIC INSTRUMENTS IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
samthamby79
 
COMMON BIASES IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
COMMON BIASES IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdfCOMMON BIASES IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
COMMON BIASES IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
samthamby79
 
Drug Distribution: Pointers for newbies
Drug Distribution: Pointers for newbiesDrug Distribution: Pointers for newbies
Drug Distribution: Pointers for newbies
samthamby79
 

More from samthamby79 (20)

THE 7-STAR PHARMACIST.pdf
THE 7-STAR PHARMACIST.pdfTHE 7-STAR PHARMACIST.pdf
THE 7-STAR PHARMACIST.pdf
 
VARIOUS LAB TESTS INTERPRETATION - AN INTRO..pdf
VARIOUS LAB TESTS INTERPRETATION - AN INTRO..pdfVARIOUS LAB TESTS INTERPRETATION - AN INTRO..pdf
VARIOUS LAB TESTS INTERPRETATION - AN INTRO..pdf
 
INTERPRETATION OF RENAL FUNCTION TESTS.pdf
INTERPRETATION OF RENAL FUNCTION TESTS.pdfINTERPRETATION OF RENAL FUNCTION TESTS.pdf
INTERPRETATION OF RENAL FUNCTION TESTS.pdf
 
INTERPRETATION OF HEPATIC FUNCTION TESTS.pdf
INTERPRETATION OF HEPATIC FUNCTION TESTS.pdfINTERPRETATION OF HEPATIC FUNCTION TESTS.pdf
INTERPRETATION OF HEPATIC FUNCTION TESTS.pdf
 
INTERPRETATION OF PFTs.pdf
INTERPRETATION OF PFTs.pdfINTERPRETATION OF PFTs.pdf
INTERPRETATION OF PFTs.pdf
 
HAEMATOLOGICAL TESTS INTERPRETATION.pdf
HAEMATOLOGICAL TESTS INTERPRETATION.pdfHAEMATOLOGICAL TESTS INTERPRETATION.pdf
HAEMATOLOGICAL TESTS INTERPRETATION.pdf
 
PHARMACOTHERAPY POINTERS FOR ISCHEMIC STROKE [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ISCHEMIC STROKE [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR ISCHEMIC STROKE [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ISCHEMIC STROKE [MALAYSIAN CPGs].pdf
 
PHARMACOTHERAPY POINTERS FOR ANXIETY & AFFECTIVE DISORDERS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ANXIETY & AFFECTIVE DISORDERS [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR ANXIETY & AFFECTIVE DISORDERS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ANXIETY & AFFECTIVE DISORDERS [MALAYSIAN CPGs].pdf
 
PHARMACOTHERAPY POINTERS FOR SCHIZOPHRENIA [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR SCHIZOPHRENIA [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR SCHIZOPHRENIA [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR SCHIZOPHRENIA [MALAYSIAN CPGs].pdf
 
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
 
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdfPHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
 
Interpretation of Clinical Lab Data [PFTs] for Newbies.pdf
Interpretation of Clinical Lab Data [PFTs] for Newbies.pdfInterpretation of Clinical Lab Data [PFTs] for Newbies.pdf
Interpretation of Clinical Lab Data [PFTs] for Newbies.pdf
 
TDM Pointers - Salicylates & Paracetamol Poisoning.pdf
TDM Pointers - Salicylates & Paracetamol Poisoning.pdfTDM Pointers - Salicylates & Paracetamol Poisoning.pdf
TDM Pointers - Salicylates & Paracetamol Poisoning.pdf
 
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdfTDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
 
Dosage adjustment in Hepatic Failure.pdf
Dosage adjustment in Hepatic Failure.pdfDosage adjustment in Hepatic Failure.pdf
Dosage adjustment in Hepatic Failure.pdf
 
Drug Dosing in Renal Failure.pdf
Drug Dosing in Renal Failure.pdfDrug Dosing in Renal Failure.pdf
Drug Dosing in Renal Failure.pdf
 
BIOAVAILABILITY IN A NUTSHELL.pdf
BIOAVAILABILITY IN A NUTSHELL.pdfBIOAVAILABILITY IN A NUTSHELL.pdf
BIOAVAILABILITY IN A NUTSHELL.pdf
 
GENERIC AND SPECIFIC INSTRUMENTS IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
GENERIC AND SPECIFIC INSTRUMENTS IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdfGENERIC AND SPECIFIC INSTRUMENTS IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
GENERIC AND SPECIFIC INSTRUMENTS IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
 
COMMON BIASES IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
COMMON BIASES IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdfCOMMON BIASES IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
COMMON BIASES IN PHARMACOEPIDEMIOLOGICAL RESEARCH.pdf
 
Drug Distribution: Pointers for newbies
Drug Distribution: Pointers for newbiesDrug Distribution: Pointers for newbies
Drug Distribution: Pointers for newbies
 

Recently uploaded

Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 

Recently uploaded (20)

Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 

Interpretation of Clinical Lab Data [CARDIAC] for newbies.pdf

  • 1. Interpretation of Clinical Lab Data [CARDIAC] for Newbies
  • 2. Common symptoms of heart disease  Chest pain (dull, aching tightness rather than tight stabbing sensation);  Dyspnoea; Palpitations; Dizziness; Syncope; Oedema; Diagnostic Testing  Chest X-Ray (CXR): Provides info. about heart size, pulmonary circulation, and aortic abnormalities.  Echocardiogram: provides more reliable info. about chamber size, hypertrophy, valvular and congenital abnormalities.  Electrocardiogram (ECG): Indicates the cardiac rhythm; reveals conduction abnormalities; provides evidence of ventricular hypertrophy, MI, Ischemia.
  • 3. ECG  Angina Pectoris: ST depression; Flat (inverted) T-wave  STEMI: • 1st ECG change during STEMI is ‘hyperacute T waves’ which appear peaked and are related to localized hyperkalemia. These changes are rarely seen as they are transient and frequently occur prior to hospital arrival. • ST segment elevation (pertaining to the affected myocardium). • 1 mm of ST elevation in 2 contiguous leads is required to diagnose STEMI, • ST elevations are indicative of the ischemic area.
  • 5.  NSTEMI and Unstable angina: • ST-segment depression≥ 0.5 mm; negative (inverted or flat) T- waves≥ 1.0 mm • ST depressions do NOT localize to the ischemic area • ECG cannot be used to determine the location of ischemia in patients w/ NSTEMI and unstable angina.
  • 7. Ischemic ST depression is characterized by horizontal or downward sloping (if not, then ischemia is unlikely to be the cause).
  • 8. If QRS…. • > 100/min. → Tachycardia; • < 60/min. → Bradycardia;
  • 10. Exercise Stress Testing (EST or ET or ETT)  Is a test of myocardial perfusion; also determines the adequacy of CV functions;  Evaluates clinical and CV responses to exercise;  Used as a diagnostic and prognostic assessment in patients with known or suspected IHD.  Non-invasive test (conducted on a tread mill or bicycle ergometer);  Treadmill walking is preferred over the ergometer as it involves more muscle mass.
  • 11. EST (contd’.)  Principle: Controlled method to assess the balance between myocardial O2 demand and coronary blood flow under ‘stress’ (exercise is the stressor).  A (+) ET is defined as ‘1mm horizontal or downsloping depression, or elevation of the ST segment for 60-80 milliseconds after the QRS complex’.
  • 12. Nuclear Imaging  Used to detect MI or to measure myocardial function, perfusion or viability depending on the radiopharmaceutical used and the technique of imaging.  Thallium-201 (TL-201): • Rapidly taken up by the myocardium; • An image taken immediately after injection reflects the distribution of blood flow to the myocardium. • Areas of ischemia or infarction receive less TL-201 and appear dark. • Around 2 - 6 hrs. post-injection, TL-201 redistributes so that all cardiac myocytes contain a comparable concentration. Images at this time show dark areas (infarction) but normal density in ischemic areas.
  • 13.  The hypoperfused areas of the viable myocardium which had little or no TL-201 initially are called ‘Partial Defects’.  Redistribution occurs because there is a delayed washout of TL-201 from the poorly perfused myocardium resulting in less contrast between the density of TL-201 in different areas of the heart. This gives the appearance of redistribution into the previously ischemic areas.
  • 14.  To enhance the evaluation of the partial defects, a second injection of TL-201 can be used.  Areas of nil distribution are called ‘Cold Spots’ or ‘Fixed defects’ (representing infarcted myocardium). Scope of TL-201 imaging:  Useful for patients w/ • atypical chest pain to determine if IHD is the cause of symptoms. • ambiguous or false-positive ETT to determine the ETT abnormalities.  The finding of redistribution is a marker of jeopardized but viable myocardium that has important prognostic value.
  • 15.  Tc-99: To detect myocardial viability.  Antimyosin Abs: Highly specific, so, should be more better markers of myocyte necrosis. But, uptake into myocardial tissues is very low; localization is more dependent on blood flow rather than on myosin conc.  Phyenylpentadecanoic acid: assesses both myocardial perfusion and metabolism by virtue of it’s affinity for fatty acid metabolism.
  • 16. Pharmacological Stress Testing  Alternative to ETT  For patients who are unwilling or unable to undergo ETT;  Used to assess coronary perfusion;  P’cological agent produces stress by… • hyperemic (vasodilator) response, [OR] • ↑es myocardial O2 demand (heart rate and myocardial contractility);  Agents used: • Dipyridamole and Adenosine (hyperemic stress), and • Dobutamine (cardiac stress)
  • 17. Principle of Dipyridamole and Adenosine TL-201 scanning:  Related to the coronary arteriolar vasodilator props.  Dipyridamole inhibits adenosine reuptake by cells; causing an ↑ ed conc. of adenosine.  Adenosine is a very potent coronary artery vasodilator (↑es the perfusion).  Areas distal to the coronary will be hypoperfused; but these areas will get filled on redistribution indicating viable but jeopardized myocardium.  Optimal dose (based on numerous research articles): • Dipyridamole 0.142 mg/kg per min. over 4 mins. • Adenosine 0.140 mcg/kg per min. over 6 mins.
  • 18.  TL-201 (2.5 – 4 mCi) is administered… • immediately after inf. of dipyridamole, (or) • after 3 mins. of Adenosine inf.  Onset of action: • Dipyridamole (5-7 mins. post-inf.); • Adenosine (approx. 30 secs. post-inf.);
  • 19. Dobutamine:  Synthetic catecholamine;  ↑es heart rate and cardiac output ↑es myocardial O2 demand.  Ischemia develops in areas where there is ↑ in O2 demand (by stenosis which prevents the blood flow to those areas).  This can be detected by the TL-201 scanning…. • Dobutamine dose 10 – 20 mcg/kg per min. • TL-201 is administered 2-3 mins. before inf. ends.  β-blockers and CCBs may interfere w/ the heart’s response to the Dobutamine stress test. (Recommendation: Discontinue the Tx prior to the test).  Contraindicated: Aortic stenosis, uncontrolled HTN, severe ventricular arrhythymias;
  • 20. Dobutamine stress testing…  Post-MI, this test identifies patients at high risk of subsequent cardiac events.  For patients w/ suspected or k/c/o IHD,… • a positive result is an independent predictor of ‘cardiac events’; • a negative result indicates protection from cardiac death.  Showed higher diagnostic accuracy (82%) for IHD; against 87% for ETT, and 77% for dipyridamole;  Showed high sensitivity (80%) – review of 14 studies; 942 IHD patients;  Cardiac catheterization  CT scan; MRI scan
  • 21. Cardiac Enzymes Lactate Dehydrogenase (LDH1 to LDH5)  Highly distributed throughout the body w/ high concs. in the heart muscle, skeletal muscle, liver, kidney, brain, and RBCs.  LDH1, LDH2 (mainly in the heart);  LDH3 (lungs);  LDH4, LDH5 (mainly in the liver and skeletal muscles);  LDH1 is often measured after a suspected MI. This isoenzyme shows greater catalytic activity combined w/ α-OH butyrate. This substrate is measured. Post-MI, peak serum levels are achieved after 2-3 days, then declines over 7 days or more.
  • 22. LDH (contd’.)  LDH1 and LDH2: ↑es after MI, renal infarction, megaloblastic anaemia;  LDH2 and LDH3: ↑es after acute leukemia;  LDH5: ↑es after damage to liver or skeletal muscle;
  • 23. Creatine Kinase (CK)  Relatively high concs. in heart muscles, skeletal muscles, smooth muscles, brain.  Markedly ↑ed after circulation failure, MI, muscular dystrophies, exercise, and trauma.  CK has 2 protein subunits: M and B (which combine to form 3 isoenzymes BB, MM, and MB).  Cardiac tissues contain more of the CK-MB isoenzyme.  CK-MM (skeletal muscle); CK-BB (brain tissue);  ↑ed CK-MB levels indicate myocardial necrosis.
  • 24. Enzymes Rise (hrs.) Peak (hrs.) Falls CK-MB 4 – 6 12 48 – 72 hrs. LDH 12 48 – 72 7 days AST 12 24 48 hrs.
  • 25. Aspartate aminotransferase (AST)  Formerly known as Serum Glutamic-Oxaloacetic Transaminase (SGOT);  Found mainly in the cardiac and hepatic tissues;  To a lesser extent in the skeletal muscle, kidney tissue and pancreatic tissue.  ↑ed AST levels are seen 8 hrs. post-damage to the heart from MI.
  • 26. Alanine aminotransferase (ALT)  Formerly known as Serum Glutamic-Pyruvic Transaminase (SGPT);  Mainly in the liver;  To a lesser extent in the heart, skeletal muscles, and kidneys;  ALT ↑es less consistently and less markedly than AST post-MI.
  • 27. Cardiac Troponins ( ‘I’ and ‘T’)  Used in the diagnosis of MI;  Troponin-I (< 1.5 ng/ml); Troponin-T (< 0.1 ng/ml);  Troponin-I (only in cardiac muscle);  Troponin-T (in cardiac and skeletal muscles);  Troponin-T has shown prognostic value in unstable angina and detecting minor myocardial injury w/ greater sensitivity than CK-MB.
  • 28. THE END (FYI Snippets follow….)
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.  P-wave (2.5 mm): R and L atrial depolarization  QRS complex (120 ms): R and L ventricular depolarization  ST segment: phase 2 of ventricular repolarization  T-wave: rapid phase 3 of ventricular repolarization;  J-point: the end of QRS and beginning of ST segment is called J-point.  PR interval: extends from beginning of P wave to beginning of the QRS. This interval measures the time from the initial depolarization of the atria to the initial depolarization of the ventricles, and reflects a physiological delay in AV conduction imposed by the AV node. Normal range is 120 – 200 ms (3 to 5 1-mm-divisions) and no longer.  QT interval: is measured from the beginning of the QRS to the end of the T wave. It represents the time in which the ventricles depolarize and repolarize and is a measure of ventricular action potential (AP) duration. Normal intervals are < 460 ms for women and < 450 ms for men. But QT values are heart-rate dependent and can vary from 270 ms at a heart rate of 150 beats/min to 500 ms at a heart rate of 40 beats/min.
  • 34.  FYI: • Anterior STEMI requires 2 mm of ST elevation in V2 and V3 in men > 40 years of age (ACC/AHA definition). A total of 2.5 mm elevation is required in men < 40 years of age, and only 1.5 mm elevation is required in women. • Posterior STEMI frequently has ST depression in V1-V3 instead of elevation since the vectors are completely reversed. If a posterior ECG were obtained, ST elevation will be seen in V7-V9, although sometimes subtle. Since these posterior changes occur from coronary thrombosis and urgent treatment is needed, it is classified as a STEMI. • (courtesy ACC and AHA) • What is V1-V9????